サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1610033

去勢抵抗性前立腺がんの市場規模、シェア、動向分析レポート：治療法別、地域別、セグメント予測、2025年～2030年

Castrate-resistant Prostate Cancer Market Size, Share & Trends Analysis Report By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 90 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
去勢抵抗性前立腺がんの市場規模、シェア、動向分析レポート：治療法別、地域別、セグメント予測、2025年～2030年
出版日: 2024年11月11日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

去勢抵抗性前立腺がん市場の成長と動向

世界の去勢抵抗性前立腺がん（CRPC）市場規模は、2030年には214億4,000万米ドルに達すると予測され、2025～2030年にかけてCAGR 8.7％で成長すると予測されています。

この成長は、去勢抵抗性前立腺がんの世界の負担増と不健康なライフスタイルが原動力となっています。

また、新製品の発売が見込まれ、前立腺がんに対する認識が高まっていることも、予測期間中の市場成長率を高めるとみられます。さらに、新規薬剤の採用拡大や強力なパイプラインは、予測期間中の市場成長を加速させる要因であると考えられます。

ホルモン療法セグメントは、CRPC管理における先進ホルモン療法の有効性により、2024年の売上高シェア42.2%で世界の去勢抵抗性前立腺がん市場を独占しました。このセグメントを牽引しているのは、Xtandi（エンザルタミド）の市場浸透率の上昇と、米国、欧州、日本におけるErleada（アパルタミド）の発売です。さらに、Xtandiの追加適応症の開発と承認が同セグメントの成長を牽引しています。また、免疫療法は、予測期間中に上市が予定されている強力なパイプライン医薬品の存在により、最も急成長しているセグメントと推定・予測されます。

北米の圧倒的なシェアは、高い疾病負担、技術の進歩、政府の積極的な施策、疾病に対する消費者の認識向上、医療インフラの改善などに起因しています。この地域に主要企業が存在することも、同地域の市場成長を後押しする重要な要因です。加えて、インドや中国などの新興諸国では、この疾患の罹患率が高く、その結果、改善された治療に対する需要の増加、医療費の増加、腫瘍学やその他の研究活動に対する政府資金の増加が見られます。このため、予測期間中、これらの要因がアジア太平洋の市場を牽引すると予想されます。

この市場には、Sanofi、Johnson and Johnson Services, Inc.、Pfizer, Inc.、Astellas Pharma, Inc.、Bayer AGといった有力企業が存在するため、高い資本要件を満たすことが難しく、新規参入の機会が大幅に減少しています。主要参入企業は、市場でのプレゼンスを維持し、市場シェアを獲得するために、新薬開発に多額の投資を行っています。

去勢抵抗性前立腺がん市場レポートハイライト

  • ホルモン療法セグメントは、CRPC管理における先進ホルモン療法の有効性により、2024年の売上高シェア42.2%で世界の去勢抵抗性前立腺がん市場を独占しました。
  • 免疫療法セグメントは、CRPC患者において持続的な反応をもたらし、全生存期間を改善する免疫療法の可能性が認識されつつあることを背景に、2025～2030年にかけてCAGR 11.9％で成長すると予測されています。
  • 2024年の去勢抵抗性前立腺がんの世界市場において、北米が47.9%と最大の売上シェアを占めています。
  • アジア太平洋の去勢抵抗性前立腺がん市場は、中国、日本、インドなどの人口密度の高い国々における前立腺がんの有病率の増加により、予測期間を通じて最も急速に成長すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 去勢抵抗性前立腺がん市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 去勢抵抗性前立腺がん市場：治療法ビジネス分析

  • セラピー市場シェア、2024年と2030年
  • 治療法セグメントダッシュボード
  • 市場規模と予測と動向分析、治療法別、2018～2030年
  • 化学療法
  • ホルモン療法
  • 免疫療法
  • 放射線治療

第5章 去勢抵抗性前立腺がん市場：治療法、地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • タイ
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Bayer AG
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 4. Castrate-resistant prostate cancer market, by region, 2018 - 2030 (USD Million)
  • Table 5. North America castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 6. North America castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 7. U.S. castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 8. Canada castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 9. Mexico castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 10. Europe castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 11. Europe castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 12. UK castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 13. Germany castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 14. France castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 15. Italy castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 16. Spain castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 17. Norway castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 18. Sweden castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 19. Denmark castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 20. Asia Pacific castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 21. Asia Pacific castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 22. China castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 23. Japan castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 24. India castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 25. Thailand castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 26. South Korea castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 27. Australia castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 28. Latin America castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 29. Latin America crowns and bridges market, by therapy, 2018 - 2030 (USD Million)
  • Table 30. Brazil castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 31. Agrnetina castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 32. Middle East & Africa castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 33. Middle East & Africa crowns and bridges market, by therapy, 2018 - 2030 (USD Million)
  • Table 34. South Africa castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 35. Saudi Arabia castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 36. UAE castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 37. Kuwait castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Castrate-resistant prostate cancer market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Castrate-resistant prostate cancer market dynamics
  • Fig. 11 Castrate-resistant prostate cancer market: Porter's five forces analysis
  • Fig. 12 Castrate-resistant prostate cancer market: PESTLE analysis
  • Fig. 13 Castrate-resistant prostate cancer market: Therapy segment dashboard
  • Fig. 14 Castrate-resistant prostate cancer market: Therapy market share analysis, 2024 & 2030
  • Fig. 15 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 16 Hormonal Therapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Radiotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Castrate-resistant prostate cancer market revenue, by region
  • Fig. 20 Region marketplace: Key takeaways
  • Fig. 21 North America region dynamics
  • Fig. 22 North America castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. country dynamics
  • Fig. 24 U.S. castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 25 Canada country dynamics
  • Fig. 26 Canada castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 27 Mexico country dynamics
  • Fig. 28 Mexico castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 29 Europe region dynamics
  • Fig. 30 Europe castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific region dynamics

  • Fig. 48 Asia Pacific castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 49 China country dynamics
    • Fig. 50 China castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand country dynamics
  • Fig. 58 Thailand castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America region dynamics
  • Fig. 64 Latin America castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East & Africa region dynamics
  • Fig. 70 Middle East & Africa castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait castrate-resistant prostate cancer market, 2018 - 2030 (USD Million
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework
    • 目次
    Product Code: GVR-4-68039-237-3

    Castrate-resistant Prostate Cancer Market Growth & Trends:

    The global castrate-resistant prostate cancer market size is expected to reach USD 21.44 billion in 2030 and is projected to grow at a CAGR of 8.7% from 2025 to 2030. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.

    In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.

    The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.

    North America's dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.

    The presence of prominent players such as Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma, Inc.; and Bayer AG in this market space significantly diminishes the opportunities of a new entry as it is difficult to match the high capital requirements. Key players are investing highly in the development of new molecules to maintain their presence in the market and acquire market share.

    Castrate-resistant Prostate Cancer Market Report Highlights:

    • The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC.
    • The immunotherapy segment is projected to grow at a CAGR of 11.9% from 2025 to 2030, driven by the increasing recognition of immunotherapy's potential to provide durable responses and improve overall survival in CRPC patients
    • North America held the largest revenue share of 47.9% of the global castrate-resistant prostate cancer market in 2024
    • Asia Pacific castrate-resistant prostate cancer market is anticipated to grow fastest throughout the forecast period, driven by the increasing prevalence of prostate cancer in densely populated countries such as China, Japan, and India

    Table of Contents

    Chapter 1. Methodology and Scope

    • 1.1. Market Segmentation & Scope
    • 1.2. Segment Definitions
      • 1.2.1. Therapy
    • 1.3. Estimates and Forecast Timeline
    • 1.4. Research Methodology
    • 1.5. Information Procurement
      • 1.5.1. Purchased Database
      • 1.5.2. GVR's Internal Database
      • 1.5.3. Secondary Sources
      • 1.5.4. Primary Research
    • 1.6. Information Analysis
      • 1.6.1. Data Analysis Models
    • 1.7. Market Formulation & Data Visualization
    • 1.8. Model Details
      • 1.8.1. Commodity Flow Analysis
    • 1.9. List of Secondary Sources
    • 1.10. Objectives

    Chapter 2. Executive Summary

    • 2.1. Market Snapshot
    • 2.2. Segment Snapshot
    • 2.3. Competitive Landscape Snapshot

    Chapter 3. Castrate-resistant Prostate Cancer Market Variables, Trends, & Scope

    • 3.1. Market Lineage Outlook
    • 3.2. Market Dynamics
      • 3.2.1. Market Driver Analysis
      • 3.2.2. Market Restraint Analysis
    • 3.3. Business Environment Analysis
      • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
        • 3.3.1.1. Supplier power
        • 3.3.1.2. Buyer power
        • 3.3.1.3. Substitution threat
        • 3.3.1.4. Threat of new entrant
        • 3.3.1.5. Competitive rivalry
      • 3.3.2. PESTLE Analysis

    Chapter 4. Castrate-resistant Prostate Cancer Market: Therapy Business Analysis

    • 4.1. Therapy Market Share, 2024 & 2030
    • 4.2. Therapy Segment Dashboard
    • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
    • 4.4. Chemotherapy
      • 4.4.1. Chemotherapy market, 2018 - 2030 (USD Million)
    • 4.5. Hormonal Therapy
      • 4.5.1. Hormonal Therapy market, 2018 - 2030 (USD Million)
    • 4.6. Immunotherapy
      • 4.6.1. Immunotherapy market, 2018 - 2030 (USD Million)
    • 4.7. Radiotherapy
      • 4.7.1. Radiotherapy market, 2018 - 2030 (USD Million)

    Chapter 5. Castrate-resistant Prostate Cancer Market: Region Estimates & Trend Analysis by Therapy

    • 5.1. Region Market Share Analysis, 2024 & 2030
    • 5.2. Region Market Dashboard
    • 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
    • 5.4. North America
      • 5.4.1. North America castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2. U.S.
        • 5.4.2.1. Key country dynamics
        • 5.4.2.2. Regulatory framework
        • 5.4.2.3. Competitive insights
        • 5.4.2.4. U.S. castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.3. Canada
        • 5.4.3.1. Key country dynamics
        • 5.4.3.2. Regulatory framework
        • 5.4.3.3. Competitive insights
        • 5.4.3.4. Canada castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.4. Mexico
        • 5.4.4.1. Key country dynamics
        • 5.4.4.2. Regulatory framework
        • 5.4.4.3. Competitive insights
        • 5.4.4.4. Mexico castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5. Europe
      • 5.5.1. Europe castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.2. UK
        • 5.5.2.1. Key country dynamics
        • 5.5.2.2. Regulatory framework
        • 5.5.2.3. Competitive insights
        • 5.5.2.4. UK castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.3. Germany
        • 5.5.3.1. Key country dynamics
        • 5.5.3.2. Regulatory framework
        • 5.5.3.3. Competitive insights
        • 5.5.3.4. Germany castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.4. France
        • 5.5.4.1. Key country dynamics
        • 5.5.4.2. Regulatory framework
        • 5.5.4.3. Competitive insights
        • 5.5.4.4. France castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.5. Italy
        • 5.5.5.1. Key country dynamics
        • 5.5.5.2. Regulatory framework
        • 5.5.5.3. Competitive insights
        • 5.5.5.4. Italy castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.6. Spain
        • 5.5.6.1. Key country dynamics
        • 5.5.6.2. Regulatory framework
        • 5.5.6.3. Competitive insights
        • 5.5.6.4. Spain castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.7. Norway
        • 5.5.7.1. Key country dynamics
        • 5.5.7.2. Regulatory framework
        • 5.5.7.3. Competitive insights
        • 5.5.7.4. Norway castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.8. Sweden
        • 5.5.8.1. Key country dynamics
        • 5.5.8.2. Regulatory framework
        • 5.5.8.3. Competitive insights
        • 5.5.8.4. Sweden castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.5.9. Denmark
        • 5.5.9.1. Key country dynamics
        • 5.5.9.2. Regulatory framework
        • 5.5.9.3. Competitive insights
        • 5.5.9.4. Denmark castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6. Asia Pacific
      • 5.6.1. Asia Pacific castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.2. Japan
        • 5.6.2.1. Key country dynamics
        • 5.6.2.2. Regulatory framework
        • 5.6.2.3. Competitive insights
        • 5.6.2.4. Japan castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.3. China
        • 5.6.3.1. Key country dynamics
        • 5.6.3.2. Regulatory framework
        • 5.6.3.3. Competitive insights
        • 5.6.3.4. China castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.4. India
        • 5.6.4.1. Key country dynamics
        • 5.6.4.2. Regulatory framework
        • 5.6.4.3. Competitive insights
        • 5.6.4.4. India castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.5. Thailand
        • 5.6.5.1. Key country dynamics
        • 5.6.5.2. Regulatory framework
        • 5.6.5.3. Competitive insights
        • 5.6.5.4. Thailand castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.6. South Korea
        • 5.6.6.1. Key country dynamics
        • 5.6.6.2. Regulatory framework
        • 5.6.6.3. Competitive insights
        • 5.6.6.4. South Korea castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.6.7. Australia
        • 5.6.7.1. Key country dynamics
        • 5.6.7.2. Regulatory framework
        • 5.6.7.3. Competitive insights
        • 5.6.7.4. Australia castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7. Latin America
      • 5.7.1. Latin America castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.7.2. Brazil
        • 5.7.2.1. Key country dynamics
        • 5.7.2.2. Regulatory framework
        • 5.7.2.3. Competitive insights
        • 5.7.2.4. Brazil castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.7.3. Argentina
        • 5.7.3.1. Key country dynamics
        • 5.7.3.2. Regulatory framework
        • 5.7.3.3. Competitive insights
        • 5.7.3.4. Argentina castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8. Middle East & Africa
      • 5.8.1. Middle East & Africa castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.2. South Africa
        • 5.8.2.1. Key country dynamics
        • 5.8.2.2. Regulatory framework
        • 5.8.2.3. Competitive insights
        • 5.8.2.4. South Africa castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.3. Saudi Arabia
        • 5.8.3.1. Key country dynamics
        • 5.8.3.2. Regulatory framework
        • 5.8.3.3. Competitive insights
        • 5.8.3.4. Saudi Arabia castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.4. UAE
        • 5.8.4.1. Key country dynamics
        • 5.8.4.2. Regulatory framework
        • 5.8.4.3. Competitive insights
        • 5.8.4.4. UAE castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.8.5. Kuwait
        • 5.8.5.1. Key country dynamics
        • 5.8.5.2. Regulatory framework
        • 5.8.5.3. Competitive insights
        • 5.8.5.4. Kuwait castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)

    Chapter 6. Competitive Landscape

    • 6.1. Participant Overview
    • 6.2. Company Market Position Analysis
    • 6.3. Company Categorization
    • 6.4. Strategy Mapping
    • 6.5. Company Profiles/Listing
      • 6.5.1. Sanofi
        • 6.5.1.1. Overview
        • 6.5.1.2. Financial performance
        • 6.5.1.3. Material benchmarking
        • 6.5.1.4. Strategic initiatives
      • 6.5.2. Johnson & Johnson Services, Inc.
        • 6.5.2.1. Overview
        • 6.5.2.2. Financial performance
        • 6.5.2.3. Material benchmarking
        • 6.5.2.4. Strategic initiatives
      • 6.5.3. Pfizer, Inc.
        • 6.5.3.1. Overview
        • 6.5.3.2. Financial performance
        • 6.5.3.3. Material benchmarking
        • 6.5.3.4. Strategic initiatives
      • 6.5.4. Astellas Pharma, Inc.
        • 6.5.4.1. Overview
        • 6.5.4.2. Financial performance
        • 6.5.4.3. Material benchmarking
        • 6.5.4.4. Strategic initiatives
      • 6.5.5. Bayer AG
        • 6.5.5.1. Overview
        • 6.5.5.2. Financial performance
        • 6.5.5.3. Material benchmarking
        • 6.5.5.4. Strategic initiatives